Timothy H M To1,2,3, Thomas W LeBlanc4, Peter Eastman5, Karen Neoh6, Meera R Agar7, Luen Bik To8, Debra Rowett9, Zac Vandersman1, David C Currow1. 1. 1 Palliative and Supportive Services, Flinders University , Adelaide, Australia . 2. 2 Southern Adelaide Palliative Services, Repatriation General Hospital , Adelaide, Australia . 3. 3 Department of Rehabilitation and Aged Care, Repatriation General Hospital , Adelaide, Australia . 4. 4 Duke University Medical Center , Durham, North Carolina. 5. 5 Barwon Health , Geelong, Australia . 6. 6 Academic Unit of Palliative Care, Leeds Institute of Health Sciences, School of Medicine, University of Leeds , Leeds, United Kingdom . 7. 7 University of Technology Sydney , Ultimo, Australia . 8. 8 Directorate of Haematology , SA Pathology, Adelaide, Australia . 9. 9 Drug and Therapeutics Information Service, Repatriation General Hospital , Adelaide, Australia .
Abstract
BACKGROUND: Red Blood Cell (RBC) transfusions are commonly used in palliative care. RBCs are a finite resource, transfusions carry risks, and the net effect (benefits and harms) is poorly defined for people with life-limiting illnesses. OBJECTIVE: To examine the indications and effects of RBC transfusion in palliative care patients. DESIGN: This international, multisite, prospective consecutive cohort study. SETTING/ SUBJECTS: Palliative care patients undergoing RBC transfusion. MEASUREMENTS: Target symptoms (fatigue, breathlessness, generalized weakness, or dizziness) were assessed before transfusion and at day 7 by treating clinicians, using National Cancer Center Institute Common Terminology Criteria for Adverse Events. Assessment of harms was made at day 2. RESULTS: One hundred and one transfusions with day 7 follow-up were collected. Median age was 72.0 (interquartile range 61.5-83.0) years, 58% men, and mean Australia-modified Karnofsky Performance Status (AKPS) of 48 (standard deviation [SD] 17). A mean 2.1 (SD 0.6) unit was tranfused. The target symptoms were fatigue (61%), breathlessness (16%), generalized weakness (12%), dizziness (6%), or other (5%). Forty-nine percent of transfusions improved the primary target symptom, and 78% of transfusions improved at least one of the target symptoms. Harms were infrequent and mild. An AKPS of 40%-50% was associated with higher chances of symptomatic benefit in the target symptom; however, no other predictors of response were identified. CONCLUSIONS: In the largest prospective consecutive case series to date, clinicians generally reported benefit, with minimal harms. Ongoing work is required to define the optimal patient- and clinician-reported hematological and functional outcome measures to optimize the use of donor blood and to minimize transfusion-associated risk.
BACKGROUND: Red Blood Cell (RBC) transfusions are commonly used in palliative care. RBCs are a finite resource, transfusions carry risks, and the net effect (benefits and harms) is poorly defined for people with life-limiting illnesses. OBJECTIVE: To examine the indications and effects of RBC transfusion in palliative care patients. DESIGN: This international, multisite, prospective consecutive cohort study. SETTING/ SUBJECTS: Palliative care patients undergoing RBC transfusion. MEASUREMENTS: Target symptoms (fatigue, breathlessness, generalized weakness, or dizziness) were assessed before transfusion and at day 7 by treating clinicians, using National Cancer Center Institute Common Terminology Criteria for Adverse Events. Assessment of harms was made at day 2. RESULTS: One hundred and one transfusions with day 7 follow-up were collected. Median age was 72.0 (interquartile range 61.5-83.0) years, 58% men, and mean Australia-modified Karnofsky Performance Status (AKPS) of 48 (standard deviation [SD] 17). A mean 2.1 (SD 0.6) unit was tranfused. The target symptoms were fatigue (61%), breathlessness (16%), generalized weakness (12%), dizziness (6%), or other (5%). Forty-nine percent of transfusions improved the primary target symptom, and 78% of transfusions improved at least one of the target symptoms. Harms were infrequent and mild. An AKPS of 40%-50% was associated with higher chances of symptomatic benefit in the target symptom; however, no other predictors of response were identified. CONCLUSIONS: In the largest prospective consecutive case series to date, clinicians generally reported benefit, with minimal harms. Ongoing work is required to define the optimal patient- and clinician-reported hematological and functional outcome measures to optimize the use of donor blood and to minimize transfusion-associated risk.
Entities:
Keywords:
anemia; blood transfusion; fatigue; palliative care
Authors: Elizabeth St Lezin; Matthew S Karafin; Roberta Bruhn; Dhuly Chowdhury; Lirong Qu; Walter Bialkowski; Scott Merenda; Pamela D'Andrea; Anne-Lyne McCalla; Lisa Anderson; Sheila M Keating; Mars Stone; Edward L Snyder; Donald Brambilla; Edward L Murphy; Philip J Norris; Joan F Hilton; Bryan R Spencer; Steven Kleinman; Jeffrey L Carson Journal: Transfusion Date: 2019-03-18 Impact factor: 3.157
Authors: Karen Neoh; Ross Gray; John Grant-Casey; Lise Estcourt; Catherine Malia; Jason W Boland; Michael I Bennett Journal: Palliat Med Date: 2018-09-27 Impact factor: 4.762
Authors: Kieran L Quinn; Amy T Hsu; Christopher Meaney; Danial Qureshi; Peter Tanuseputro; Hsien Seow; Colleen Webber; Rob Fowler; James Downar; Russell Goldman; Raphael Chan; Kimberlyn McGrail; Sarina R Isenberg Journal: Palliat Med Date: 2021-03-30 Impact factor: 4.762